These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8885822)

  • 1. Immunogenicity of a recombinant hepatitis B vaccine in adults.
    Bock HL; Kruppenbacher J; Sänger R; Höbel W; Clemens R; Jilg W
    Arch Intern Med; 1996 Oct; 156(19):2226-31. PubMed ID: 8885822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
    Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.
    Wiedmann M; Liebert UG; Oesen U; Porst H; Wiese M; Schroeder S; Halm U; Mössner J; Berr F
    Hepatology; 2000 Jan; 31(1):230-4. PubMed ID: 10613751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Humoral immunity level and factors associated with the response to the vaccine against the hepatitis B virus in health personnel of the Case-Essalud National Hospital, Arequipa September 1995-March 2002].
    Campos Nizama J
    Rev Gastroenterol Peru; 2005; 25(2):141-9. PubMed ID: 16021199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines.
    Zuckerman JN; Zuckerman AJ; Symington I; Du W; Williams A; Dickson B; Young MD;
    Hepatology; 2001 Oct; 34(4 Pt 1):798-802. PubMed ID: 11584378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years.
    Kurugöl Z; Mutlubaş F; Ozacar T
    Vaccine; 2005 Apr; 23(22):2876-80. PubMed ID: 15780736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
    Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
    Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
    Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
    Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth.
    Jafarzadeh A; Montazerifar SJ
    J Ayub Med Coll Abbottabad; 2006; 18(4):4-9. PubMed ID: 17591001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance to hepatitis B vaccination and subsequent development of seroprotection among health care workers of a tertiary care center of Saudi Arabia.
    Panhotra BR; Saxena AK; Al-Hamrani HA; Al-Mulhim A
    Am J Infect Control; 2005 Apr; 33(3):144-50. PubMed ID: 15798668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease.
    Keeffe EB; Iwarson S; McMahon BJ; Lindsay KL; Koff RS; Manns M; Baumgarten R; Wiese M; Fourneau M; Safary A; Clemens R; Krause DS
    Hepatology; 1998 Mar; 27(3):881-6. PubMed ID: 9500723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.